CHINESE JOURNAL OF DRUG EVALUATION >

2026 , Vol. 43 >Issue 2: 128 - 128-132

DOI: https://doi.org/10.2095-3593.2026.040008

Effect of Qingjin Huatan Decoction on the Nrf2/HO-1 Signaling Pathway and Symptom Recovery in Chronic Obstructive Pulmonary Disease

  • 彬 张
Expand
  • Department of Respiratory and Gastroenterology， the 988th Hospital (Jiaozuo Branch) of the Joint Logistics
         Support Force of the People′s Liberation Army， Henan Jiaozuo 454000， China

Received date: 2025-10-31

  Revised date: 2025-12-23

  Accepted date: 2026-05-19

  Online published: 2026-05-19

Fold

Abstract

Objective： To observe of the effect of Qingjin huatan decoction on Nrf2/HO-1 and symptom recovery in patients with chronic obstructive pulmonary disease（COPD）. Methods： A prospective study was conducted on 118 COPD patients who visited our hospital from September 2023 to May 2025， and a parallel controlled trial was designed. They were divided into a control group and an experimental group using a simplified random number table method， with 59 cases in each group. The control group received conventional Western medicine treatment， while the experimental group received Qingjin Huatan decoction combined with conventional Western medicine. The syndrome scores， Nrf2/HO-1 signaling pathway proteins， oxidative stress， inflammatory indicators and rehabilitation process of the two groups of patients were compared. Analyze the correlation between Nrf2/HO-1 signaling pathway proteins and clinical indicators. Results： After treatment， the scores of symptoms such as cough with yellow phlegm， chest stuffiness and asthma， fever and thirst and restlessness in the experimental group were lower than those in the control group (P<0.05). The relative expression levels of serum Nrf2 and HO-1 in the experimental group were higher than those in the control group (P<0.05). The level of SOD in the experimental group was higher than that in the control group， while the MDA， WBC and Neu were lower than those in the control group (P<0.05). The relief time of dyspnea， cough， sputum and activity tolerance in the experimental group were lower than those in the control group (P<0.05). Nrf2 and HO-1 are positively correlated with SOD and negatively correlated with MDA， WBC and Neu (r=0.745， -0.802， -0.739， -0.779， 0.795， -0.773， -0.725， -0.719； P<0.05). Conclusion： Qingjin huatan decoction can alleviate the clinical symptoms of COPD patients， and has a positive effect on reducing oxidative stress， inflammatory response and accelerating the recovery process of patients. Its mechanism of action may be related to the activation of the Nrf2/HO-1 pathway.

Key words： ; font-size:medium; ">Chronic obstructive pulmonary disease； Qingjin huatan decoction； Nuclear factor E2 related factor 2/heme oxygenase 1； Syndrome score； Rehabilitation process

Cite this article

彬 张 . Effect of Qingjin Huatan Decoction on the Nrf2/HO-1 Signaling Pathway and Symptom Recovery in Chronic Obstructive Pulmonary Disease[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2026 , 43(2) : 128 -128-132 . DOI: 10.2095-3593.2026.040008

References

 [1] 罗智敏，皮建彬，王文会. 基于NHANES分析LE8与慢性阻塞性肺疾病发病风险的关系[J]. 中南医学科学杂志，2025，53(2)：267-271.
     [2] 陈晓玲，潘志斌，顾雨芹，等. 氟喹诺酮类和非氟喹诺酮类抗生素在非复杂慢性阻塞性肺疾病急性加重期中的效用对比研究[J]. 黑龙江医学，2024，48(13)：1595-1598.
     [3] 焦莉，赵玲艳，刘静. 麦杏补肺汤联合沙美特罗替卡松对慢性阻塞性肺疾病患者肺功能及炎症指标的影响[J]. 淮海医药，2024，42(4)：414-417.
     [4] 李晓娜，侯帅辉，王才利. 清肺养阴汤联合无创通气对慢性阻塞性肺疾病的治疗效果[J]. 华夏医学，2024，37(3)：151-156.
     [5] 欧阳茜，王莉莉. 清金化痰汤联合中医定向透药治疗支气管扩张症（痰热壅肺证）的临床效果[J]. 中国医学创新，2025，22(27)：118-121.
     [6] Liu ZJ， Wei JH， Sun HB，et al. Plumbagin ameliorates lps-induced acute lung injury by regulating PI3K/AKT/mTOR and Keap1-Nrf2/HO-1 signalling pathways[J]. J Cell Mol Med， 2024，28(13)：e18386.
     [7] Cornelius Teresa. Clinical guideline highlights for the hospitalist： GOLD COPD update 2024[J]. J Hosp Med， 2024，19(9)：818-820.
     [8] 李建生，冯贞贞，张海龙，等. 慢性阻塞性肺疾病急性加重危险窗期中医证候诊断标准（2025）[J]. 中医杂志，2025，66(18)：1958-1961.
     [9] Calverley PMA， Walker PP. Contemporary concise review 2022： chronic obstructive pulmonary disease[J]. Respirology，2023，28(5)：428-436.
     [10] 陈鲍辉，尹欣，徐柯，等. 上海市嘉定区居民慢性阻塞性肺疾病知识知晓情况及影响因素调查[J]. 复旦学报(医学版)，2025，52(5)：737-742.
     [11] 吴超贤，胡恬莎，王媛媛. 公共健康管理策略在慢性阻塞性肺疾病管理中的应用[J]. 中国卫生产业，2025，22(16)：214-217.
     [12] Stenmanns C， Frohnhofen H， Munks-lederer C，et al. Inhalation treatment of chronic obstructive pulmonary disease (COPD) in older patients[J]. Z Gerontol Geriatr， 2025，58(2)：97-102.
     [13] 刘顺治，崔红生，弓雪峰. 基于“气火失衡”的慢性阻塞性肺疾病病机与治疗探析[J]. 中医杂志，2025，66(19)：2056-2060.
     [14] Cao Xia， Wang Yi， Chen Ying，et al. Advances in traditional Chinese medicine for the treatment of chronic obstructive pulmonary disease[J]. J Ethnopharmacol， 2023，10(307)：116229.
     [15] 杨淇煜，杨胜利. 从肺脾肾论治慢性阻塞性肺疾病验案举隅[J]. 光明中医，2025，40(11)：2254-2257.
     [16] 陈淳，高景蓬. 清金化痰汤加味治疗痰热郁肺型肺风痰喘的临床研究[J]. 浙江中医杂志，2025，60(6)：480-482.
     [17] Liu Ting， Li Yang， HU Nan. Aucubin alleviates chronic obstructive pulmonary disease by activating Nrf2/HO-1 signaling pathway[J]. Cell Biochem Biophys， 2024，82(3)：2439-2454.
     [18] 孙学功，张胜，张永楠. 清金化痰汤联合美罗培南治疗老年重症肺炎临床研究[J]. 新中医，2025，57(19)：33-38.
     [19] 吴明先，杨曦，廖蔚林，等. 黄芩苷治疗心血管疾病的药理作用研究进展[J]. 现代药物与临床，2025，40(9)：2406-2412.
     [20] 陈乐，厉鹤，毛李仲. 清金化痰汤联合五苓散加减方治疗慢性阻塞性肺疾病急性加重期阳虚水泛兼痰热郁肺证的短期疗效[J]. 中国药物与临床，2025，25(18)：1197-1202.
Options
Outlines

/

〈 〉

[an error occurred while processing this directive]